Selective 5-HT2B Antagonists for Migraine and IBS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on 5-HT 2B receptors is limited due to their high homology with close members, making it difficult to discover highly selective antagonists, which hampers the understanding of their roles and therapeutic applications for conditions like migraine, irritable bowel syndrome, pulmonary arterial hypertension, and fibrosis.
Innovation Solution
Development of novel 5-HT 2B antagonists with specific chemical structures, such as those described by formulas I and II, which are designed to selectively bind to the 5-HT 2B receptor, allowing for the treatment of disorders associated with undesirable 5-HT 2B signaling, including migraine, irritable bowel syndrome, pulmonary arterial hypertension, fibrosis, and cardiovascular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antagonists are used, then general 5-HT receptor activity is modulated, but selectivity for 5-HT 2B receptor is insufficient
Solution Approach 1:
The antagonist molecule is divided into distinct functional segments: a basic amine head group for ionic interaction with Asp3.32, a rigidifying aromatic ring system for π-stacking with Phe6.44 and Trp5.48, and substitutable R-groups for fine-tuning selectivity. This segmentation allows each part to contribute specifically to 5-HT 2B binding while enabling modular optimization of selectivity without proportionally increasing overall complexity.
Solution Approach 2:
Specific local chemical features are introduced at key positions: a basic nitrogen atom for ionic bonding, aromatic rings for π-stacking, and hydrophobic substituents for van der Waals interactions. These localized quality enhancements at critical binding sites provide high selectivity for 5-HT 2B receptor without requiring complex modification of the entire molecular structure.
2Reliability
If highly selective 5-HT 2B antagonists are developed, then therapeutic efficacy for specific disorders is improved, but understanding of receptor roles in various conditions is limited
Solution Approach 1:
The patent employs a series of intermediary compounds with gradually increasing selectivity for 5-HT 2B receptor. These intermediary structures serve as chemical probes that allow systematic investigation of receptor functions in various physiological conditions while providing progressively better therapeutic efficacy, thereby reducing information loss about receptor roles.
3Reliability
If novel chemical structures are designed for selective binding, then selectivity over other 5-HT receptors is improved, but difficulty in discovering highly selective antagonists increases
Solution Approach 1:
The patent systematically varies key molecular parameters such as the basic amine pKa, aromatic ring substitution patterns, and hydrophobic group characteristics to optimize 5-HT 2B selectivity. By controlling and adjusting these specific parameters, the discovery process becomes more systematic and less difficult, while achieving high selectivity.
Data Source
AI summary
The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.